NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cellphire Therapeutics

Cellphire Therapeutics

Private
Rockville, MarylandHealthcare & Life Scienceshttps://www.cellphire.com/

Last Round

Series A

Apr 2, 2021

Total Funding Raised

$104.25M

Company Overview

Cellphire Therapeutics is a clinical-stage biotechnology company that develops next-generation platelet-derived therapeutics to treat hemorrhaging.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Defense Tech, Pharma Supply Chain

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

platelet therapeuticslong shelf-life plateletscryopreserved plateletsCPPfreeze-dried plateletshemostatic agentbleeding controlstabilized plateletstrauma caremilitary medicinebattlefield medicineemergency preparednessmass casualty responsegovernment contractsallogeneic therapeuticscGMP manufacturingtraumatic brain injuryTBIveterinary medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cellphire Therapeutics Comparables

Compare Cellphire Therapeutics with similar companies based on industry and business-model similarity.

Cellphire Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Haima Therapeutics
81%
Cayuga Biotech
73%
Velico Medical
72%

Cellphire Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 2, 2021
GrantJan 15, 2020
Early FundingJun 5, 2017
VC RoundJun 10, 2014

Key People

Founding team and executive leadership

Mike Gaffney

Chief Executive Officer

Executive Team

Cellphire Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 5, 2026

    Monthly visitors increased 37% MoM, reaching 1.6K.

  • Apr 2, 2021

    $15M round completed.

Cellphire Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cellphire Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cellphire Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersRockville, Maryland
Employee Range48
Year Founded2005
Last FundingApr 2, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.